June 18, 2008
A new research study shows that a patented niacin-bound chromium complex significantly reduces vascular inflammation compared to chromium picolinate. The results of this research were presented at the recent American Diabetes Association’s 68th Annual Scientific Sessions in San Francisco.
The 8-week study looked at blood markers for vascular inflammation, including TNF-a, MCP-1, retinol binding protein-4 (RBP-4), cholesterol, and triglycerides in obese Zucker diabetic rats. The diets of test animals were supplemented with 400 µg chromium from the niacin-bound chromium complex or chromium picolinate per kilogram of body weight.
When compared with animals in the control group, the niacin-bound chromium complex group experienced significantly lower total cholesterol and triglycerides than the group supplemented with chromium picolinate. Levels of TNF-a, MCP-1, RBP-4 were also lower in the chromium complex group than the control group, while the chromium picolinate group did not experience any reduction in those markers.
The patented niacin-bound chromium complex used during the trial was provided by InterHealth Nutraceuticals.
This study was funded by the National Institute of Diabetes and Digestive Kidney Diseases, a division of the National Institutes of Health.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Exercise recovery: Electrolytes, hydration and combating fatigue – SupplySide intensive webinarSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023